Status:
ACTIVE_NOT_RECRUITING
Risk Factors in Tachycardiomyopathy
Lead Sponsor:
University Hospital Tuebingen
Conditions:
Atrial Fibrillation
Atrial Flutter
Eligibility:
All Genders
18+ years
Brief Summary
Decision between rate control and rhythm control can be a challenge in clinical practice. While there is some guiding evidence, we still lack a comprehensive insight into different subgroups of patien...
Eligibility Criteria
Inclusion
- newly diagnosed left ventricular ejection fraction ≤ 50%
- endomyocardial biopsy available
- tachycardic rhythm disturbance with a rhythm control strategy planned for tachycardic atrial fibrillation or flutter (≥100/min) or more than 10000 ventricular premature beats in 24 hours
Exclusion
- age \<18 years
- patient unable or unwilling to give informed consent
- coronary artery stenosis \>50%
- relevant valvular disease
- simultaneous contraindications against amiodarone treatment and pulmonary vein isolation/ablation therapy
- present or suspected alcohol/drug dependency will result in exclusion from the study
Key Trial Info
Start Date :
October 11 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2030
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03418467
Start Date
October 11 2018
End Date
May 1 2030
Last Update
March 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinikum Tübingen, Medizinische Klinik III (Kardiologie)
Tübingen, Germany, 72076